A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Recruiting

Phase 2

Macupatide & EloralintideA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Sponsor:

Eli Lilly and Company

Code:

NCT07215559

Conditions

Obesity

Overweight

Diabetes Mellitus, Type 2

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Macupatide

Eloralintide

Macupatide Placebo

Eloralintide Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-11. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-06-04.